violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain magnetic tape cartridges and components thereof by reason of infringement of one or more of claims 1–19 of the '596 patent; claims 1–6 and 8 of the '501 patent; and claims 1–11 and 15–20 of the '774 patent, and whether an industry in the United States exists as required by subsection (a)(2) of section 337;

(2) Pursuant to Commission Rule 210.50(b)(1), 19 CFR 210.50(b)(1), the presiding administrative law judge shall take evidence or other information and hear arguments from the parties and other interested persons with respect to the public interest in this investigation, as appropriate, and provide the Commission with findings of fact and a recommended determination on this issue, which shall be limited to the statutory public interest factors set forth in 19 U.S.C. 1337(d)(1), (f)(1), (g)(1);

(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainants are:


Sony Storage Media Manufacturing Corporation, 3–4–1 Sakuragi, Tagajo, Miyagi 985–0842, Japan.

Sony DADC US Inc., 1800 North Fruitridge Avenue, Terre Haute, IN 47804.

Sony Latin America Inc., 5201 Blue Lagoon Drive, Suite 400, Miami, FL 33126.

(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served:


Fujifilm Media Manufacturing Co., Ltd., 12–1 Oigimachi 2-chome, Odawara, Kanagawa 250–0001, Japan.

Fujifilm Holdings America Corporation, 200 Summit Lake Drive, Valhalla, NY 10595.


Fujifilm Media Manufacturing Co., Ltd., 12–1 Oigimachi 2-chome, Odawara, Kanagawa 250–0001, Japan.

Fujifilm Holdings America Corporation, 200 Summit Lake Drive, Valhalla, NY 10595.


(c) The Office of Unfair Import Investigations, U.S. International Trade Commission, 500 E Street SW., Suite 401, Washington, DC 20436; and

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge. Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown. Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.

Issued: May 26, 2017.

Lisa R. Barton,
Secretary to the Commission.

[FR Doc. 2017–11307 Filed 5–31–17; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as manufacturers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.

<table>
<thead>
<tr>
<th>Company</th>
<th>FR docket</th>
<th>Published</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cody Laboratories, Inc</td>
<td>81 FR 61249</td>
<td>September 6, 2016</td>
</tr>
<tr>
<td>Alcamo Wisconsin Corporation</td>
<td>81 FR 63219</td>
<td>September 14, 2016</td>
</tr>
<tr>
<td>Johnson Matthey, Inc</td>
<td>81 FR 71767</td>
<td>October 18, 2016</td>
</tr>
<tr>
<td>Noramco, Inc</td>
<td>82 FR 6645</td>
<td>January 19, 2017</td>
</tr>
<tr>
<td>Organix, Inc</td>
<td>82 FR 8433</td>
<td>January 25, 2017</td>
</tr>
<tr>
<td>Mallinckrodt, LLC</td>
<td>82 FR 13136</td>
<td>March 9, 2017</td>
</tr>
<tr>
<td>Siemens Healthcare Diagnostics, Inc</td>
<td>82 FR 13506</td>
<td>March 13, 2017</td>
</tr>
</tbody>
</table>

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of these registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.
The company plans to manufacture small quantities of the listed controlled substance in bulk for distribution to its customers.

Louis J. Milione,
Assistant Administrator.

[FR Doc. 2017–11386 Filed 5–31–17; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic class, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before July 31, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on April 6, 2017, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665–2402 applied to be registered as an importer of U–47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) (9547), a basic class of controlled substance listed in schedule I.

The company plans to import small quantities of the listed controlled substance for the manufacture of analytical reference standards and distribution to their research and forensic customers.

Louis J. Milione,
Assistant Administrator.

[FR Doc. 2017–11387 Filed 5–31–17; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Application: Cerilliant Corporation

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before July 3, 2017. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before July 3, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of...